Stocks Health care NWBO
OTC · Health careNorthwest Biotherapeutics Inc (NWBO)
Northwest Biotherapeutics Inc brought in $2.2M of revenue over the twelve months to June 30, 2026, up 98.6% from a year earlier. It posted a net loss of $37.7M. In fiscal 2025 capital spending exceeded operating cash flow by $46.3M. At June 30, 2026 it held $595K in cash against $52M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Watch NWBO in 60 secondsWhat Northwest Biotherapeutics Inc does
Northwest Biotherapeutics Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker NWBO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $1.4M | -$60.2M | -$0.04 | -$46.3M |
| 2024 | $1.4M | -$83.8M | -$0.07 | -$58M |
| 2023 | $1.9M | -$62.6M | -$0.06 | n/a |
| 2022 | $1.7M | -$105M | -$0.10 | n/a |
| 2021 | $1M | $179.1M | -$0.06 | n/a |
| 2020 | $1.3M | -$529.8M | -$0.73 | n/a |
Full financial statements: income, balance sheet and cash flow
Where NWBO ranks in Health care
Latest SEC filings
What Northwest Biotherapeutics Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 14, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 516% to $807K versus the same quarter last year; diluted EPS -$0.01 versus -$0.01.
- July 31, 2026
- July 31, 2026
- July 20, 2026
- May 15, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 32% to $494K versus the same quarter last year; diluted EPS $0.00 versus -$0.01.
- April 16, 2026Form POS AM filing POS AM
- April 15, 2026Annual report 10-K · period to December 31, 2025Revenue was flat at $1.4M versus the prior year; diluted EPS -$0.04 versus -$0.07.
- April 7, 2026
- March 31, 2026Late annual report notice NT 10-K
- January 15, 2026Other event 8-K
Questions about NWBO
What does Northwest Biotherapeutics Inc do?
Northwest Biotherapeutics Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker NWBO.
Is Northwest Biotherapeutics Inc profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $37.7M on revenue of $2.2M.
How much revenue does Northwest Biotherapeutics Inc make?
Over the twelve months to June 30, 2026 Northwest Biotherapeutics Inc reported revenue of $2.2M. That is 98.6% more than a year earlier.
When did Northwest Biotherapeutics Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026.
Similar companies
Compare NWBO with
Follow NWBO
Get an email when Northwest Biotherapeutics Inc files with the SEC: results, executive changes, material agreements and annual reports.
Follow NWBO: get an email when it filesWhere the numbers come from
Financial figures are the values Northwest Biotherapeutics Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.